Enveda
Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases.
$311MSeries E
ParticipantD
Dimension
Activity from announced rounds
Activity in this selectionUnited States · Oct 25, 2026 · Jan 1, 2026
- Rounds participated in
- 3
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $711M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionChai Discovery
Building AI models to accelerate pre-clinical drug discovery
$400MSeries C
Role not disclosedEarendil Labs
Earendil Labs develops protein therapeutics using AI models coupled with experimental antibody discovery and validation.
UndisclosedFinancing rounds disclosure
Participant